Experimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agent
Φόρτωση...
Ημερομηνία
Συγγραφείς
Tsiolis, I.
Papalois, A.
Loukopoulos, I.
Gravvanis, A.
Lykoudis, E.
Theodossopoulou, E.
Chairakakis, A.
Dimitroulopoulos, D.
Sfiniadakis, I.
Vassiliou, I.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Transplant Proc
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
INTRODUCTION: Daclizumab (Dmab) is a genetically engineered humanized IgG1 monoclonal antibody that binds to the alpha chain of the interleukin-2 receptor (Tac, CD25, p55) expressed on activated human T lymphocytes. Dmab has been used in a clinical protocol of islet transplantation with satisfactory results. The aim of the present study was to evaluate the use of an antibody against the interleukin-2 receptor (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte allotransplantation (allo-Tx) in rats with fulminant hepatic failure (FHF). MATERIALS AND METHODS: Six Wistar rats were used as donors and 48 Lewis rats as recipients: four groups of 12 animals each with induction of FHF and 24 hour later hepatocyte Tx--group A: no treatment; group B: cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C: Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and cyclosporine. Hepatocytes were transplanted intrasplenically. Animals were followed for 15 days. RESULTS: Statistical analysis showed better survival among groups C (83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72, MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not significantly than group C. Biochemical evaluation and histology confirmed satisfactory function and engraftment, respectively. CONCLUSION: This experimental model showed the safe, effective use of Dmab.
Περιγραφή
Λέξεις-κλειδιά
Animals, Antibodies, Monoclonal/*therapeutic use, Antibodies, Monoclonal, Humanized, Graft Survival, Hepatocytes/*cytology/*transplantation, Immunoglobulin G/*therapeutic use, Immunosuppressive Agents/*therapeutic use, Liver Failure, Acute/*surgery, Male, Models, Animal, Rats, Rats, Inbred Lew, Rats, Wistar, Receptors, Interleukin-2/immunology, Spleen, Transplantation, Homologous/*immunology
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15919507
http://ac.els-cdn.com/S0041134505002137/1-s2.0-S0041134505002137-main.pdf?_tid=6c7f5e0f151836aebe43c26e30efa7b9&acdnat=1333466359_a0997b78a318651a2cc299834eb56de3
http://ac.els-cdn.com/S0041134505002137/1-s2.0-S0041134505002137-main.pdf?_tid=6c7f5e0f151836aebe43c26e30efa7b9&acdnat=1333466359_a0997b78a318651a2cc299834eb56de3
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής